Xtacy Therapeutics (XTCYF, $0.02) was a top loser over the last three months, falling -5 to $0.02 per share. A.I.dvisor analyzed 159 stocks in the Finance/Rental/Leasing Industry for the 3-month period ending September 3, 2024, and found that of them (6) exhibited an Uptrend while of them (3) demonstrated a Downtrend. A.I.dvisor found 559 similar cases when XTCYF's price dropped within three months. In out of those 559 cases, XTCYF's price went up during the following month. Based on these historical data, A.I. thinks the odds of a Downtrend reversal for XTCYF are